Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Participant has a diagnosis of irritable bowel syndrome (IBS) with a subtype of diarrhea defined by the Rome III criteria.~2. Participant has had a colonoscopy performed:~   * Within 10 years prior to Prescreening if participant is at least 50 years of age (sigmoidoscopy, double contrast barium enema, or computed tomography (CT) colonography within the past 5 years is acceptable)~  * Since the onset (if applicable) of any of the following alarm features for participants of any age:~     * Participant has documented weight loss within the past 6 months~    * Participant has nocturnal symptoms~    * Participant has a familial history of first-degree relatives with colon cancer or~    * Participant has blood mixed with their stool (excluding blood from hemorrhoids).~3. Female participants must be:~   * Postmenopausal, defined as 52 years or older and amenorrheic for at least 2 years at Prescreening,~  * Surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy),~  * Abstinent, or~  * If sexually active, be practicing an effective method of birth control.~Exclusion Criteria:~1. Participant has a diagnosis of IBS with a subtype of constipation, mixed IBS, or unsubtyped IBS by the Rome III criteria.~2. Participant has a history of inflammatory or immune-mediated gastrointestinal (GI) disorders including inflammatory bowel disease (ie, Crohn's disease, ulcerative colitis) and celiac disease.~3. Participant has a history of diverticulitis within 3 months prior to Prescreening.~4. Participant has a history of intestinal obstruction, stricture, toxic megacolon, GI perforation, fecal impaction, gastric banding, bariatric surgery, adhesions, ischemic colitis, or impaired intestinal circulation (eg, aortoiliac disease).~5. Participant has any of the following surgical history:~   * Cholecystectomy with any history of post cholecystectomy biliary tract pain~  * Any abdominal surgery within the 3 months prior to Prescreening~  * Participant has a history of major gastric, hepatic, pancreatic, or intestinal surgery (appendectomy, hemorrhoidectomy, or polypectomy greater than 3 months post surgery are allowed)~Other protocol-specific eligibility criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Eluxadoline 75 mg (Type: EXPERIMENTAL): Eluxadoline 75 mg tablets, orally, twice daily for up to 52 weeks period.
- Eluxadoline 100 mg (Type: EXPERIMENTAL): Eluxadoline 100 mg tablets, orally, twice daily for up to 52 weeks period.
- Placebo (Type: PLACEBO_COMPARATOR): Eluxadoline placebo matching tablets, orally, twice daily for up to 52 weeks period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete